Therapeutic Focus Areas
Current Progress
Our development priorities focus on diseases that currently have no effective treatments available, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, liver fibrosis, myocardial fibrosis along with numerous other diseases. Furthermore, we are dedicated to addressing type 2 diabetes mellitus and obesity, as well as rare and orphan diseases - cystic fibrosis, epidermolysis bullosa.
Overview:
- We currently have 22 disease-focused programmes, each protected by patents, archived in an international repository, and supported by successful pilot studies and toxicology evaluations.
- Several of these programmes have advanced further, having initiated or completed their preclinical trial phases.
​​
Legal Structure:
- Each disease-area project is incorporated as a separate subsidiary under Genetic Diagnostics & Therapy 21 Ltd., ensuring independent intellectual property rights.
- This approach allows investors to support a specific disease-area project rather than the entire parent company.
​​
Partnerships & Alliances:
- If you would like to learn more or explore collaboration opportunities, please contact us.